尿激酶经导管接触溶栓治疗急性肢体缺血初步临床应用  

Preliminary clinical application of catheter-directed thrombolysis with urokinase for acute limb ischemia

作　　者：刘玉金[1] 张孝军[2] 宋伟祥[1] 沈旭波[1] 李浏博 

机构地区：[1]上海中医药大学附属岳阳中西医结合医院介入科,200437 [2]同济大学附属第十人民医院介入血管外科

出　　处：《介入放射学杂志》2018年第3期262-265,共4页Journal of Interventional Radiology

摘　　要：目的探讨经导管灌注尿激酶接触溶栓治疗急性肢体缺血的临床效果和安全性。方法回顾性分析经UniFuse溶栓导管灌注尿激酶治疗21例急性肢体缺血患者临床资料,总结导管接触溶栓(CDT)临床疗效、预后及并发症。结果全部患者溶栓有效,临床症状缓解,保肢成功。1例因肾功能失代偿发生脑出血死亡,无其它出血、血肿、致残并发症。结论初步临床研究表明,CDT术治疗急性肢体缺血安全有效,有助于减少不必要的外科手术及支架植入,溶栓风险可控。Objective To evaluate the curative effect and feasibility of catheter-directed thrombolysis with urokinase for acute limb ischemia. Methods The clinical data of a total of 21 patients with acute limb ischemia, who were treated with infusion of urokinase through UniF use thrombolytic catheter, were retrospectively analyzed. The clinical curative efficacy, prognosis and complications of catheter-directed thrombolysis（CDT） were summarized. Results In all patients, thrombolysis therapy was effective, the clinicalsymptoms were alleviated, and successful limb salvage was achieved. One patient died of cerebral hemorrhage due to renal decompensation. No other serious complications such as hemorrhage, hematoma or disability occurred. Conclusion Preliminary clinical study shows that CDT with urokinase is effective and safe for the treatment of acute limb ischemia. This therapy can help reduce unnecessary surgical procedures or stent implantation, and the risk of thrombolysis is controllable.

关 键 词：急性肢体缺血 导管接触溶栓 尿激酶 血栓 

分 类 号：R528.1[医药卫生—内科学]